Coya Therapeutics, Inc. (COYA), a firm dedicated to enhancing regulatory T cell function, announced on Monday the promotion of its Chief Business Officer, Arun Swaminathan, to the position of Chief Executive Officer, effective November 1.
Swaminathan will succeed Howard Berman, who will continue to serve as Executive Chair.
Before joining Coya as Chief Business Officer in April 2023, Swaminathan was instrumental in executing significant commercial transactions at Alteogen Inc. and Actinium Pharmaceuticals.
Additionally, Swaminathan is the founder and former CEO of Lynkogen, Inc., a company focused on developing GLP-1 fusion proteins.
